betaSENSE

betaSENSE is transforming the landscape of protein diagnostics by focusing on the early detection of neurodegenerative diseases, such as Alzheimer`s and Parkinson`s. Emerging from pioneering research at Ruhr University Bochum, led by Prof. Dr. Klaus Gerwert, betaSENSE employs innovative technology that detects alterations in protein structures within bodily fluids. This pre-symptomatic detection provides significant advantages in personalized medical treatment and prevention strategies. The company`s proprietary betaSENSE technology is instrumental in identifying individuals at risk, helping both patients and healthcare providers to make informed decisions about initiating drug therapies or lifestyle modifications. With a team of over 30 specialists, betaSENSE leverages interdisciplinary collaboration to advance medical research and enhance self-determination in aging populations.